Report an error   
Advanced Search

Efficacy and safety of a novel tetravalent dengue vaccine in healthy children aged 2 to 14 years in Asia


Company Sanofi Pasteur

Publication Information

Publication Type
Research Project
June 8, 2011-February 25, 2014


Sanofi Pasteur is developing a chimeric yellow fever-dengue vaccine (CYD). The USAMRMC has adopted CYD into USAMMDA's Advanced Development Program. The study aims to assess the efficacy of CYD dengue vaccine after 3 vaccinations at 0, 6, and 12 months in preventing symptomatic virologically-confirmed dengue cases in children aged 2 to 14 years.

Physical Location

LocationLocation CodeAvailable FormatAvailability
US National Library of Medicine Abstract External Link (View)

©2021 HERDIN PLUS. All rights reserved.